ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1057

Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts

Eri Sugawara, Masaru Kato, Yuki Kudo, WenShi Lee, Yuichiro Fujieda, Toshiyuki Bohgaki, Olga Amengual, Kenji Oku, Shinsuke Yasuda and Tatsuya Atsumi, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autophagy, citrullinated vimentin, major histocompatibility complex (MHC), rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Citrullinated vimentin (cVIM) is one of the major autoantigens in patients with rheumatoid arthritis (RA), recognized by anti-citrullinated peptide antibodies. Autophagy is a self-cannibalism system to adapt to starvation but also regulates various cellular functions. Since autophagy is involved in antigen presentation with major histocompatibility complex (MHC) class II and accelerates peptidylarginine deiminase activity, we hypothesized that activation of autophagy causes citrullination of vimentin and its interaction with MHC class II in synovial fibroblasts (SF), one of the effector cells in RA.

Methods: SF were derived from synovial tissue specimens obtained from RA patients during joint replacement surgery. To evaluate antigen presenting capacity of SF, the cell surface expression of MHC class II and B7 molecules were analyzed by flow cytometry after 72h treatment with IFN-γ. Anti-cVIM antibodies were measured in RA patients’ sera using enzyme-linked immunosorbent assay. Intracellular citrullinated autoantigens in SF were analyzed by western blotting using anti-cVIM antibody positive patient’s serum as a primary antibody. To induce autophagy, SF were incubated in serum-free medium for 2h or treated with 10 μM of the proteasome inhibitor MG132 for 24h. To inhibit autophagy, SF were treated with 5 mM of 3-methyladenin. Intracellular cVIM was evaluated by western blotting and immunocytochemistry using anti-vimentin and -citrulline antibodies. To evaluate the interaction between MHC class II and cVIM, lysates of IFN-γ treated SF were immunoprecipitated by anti-HLA-DR antibody, followed by western blotting for vimentin and citrulline. In addition, proximity ligation assay was performed using anti-HLA-DR, -vimentin, and -citrulline antibodies.

Results: MHC class II, B7-H1, and B7-DC were expressed on SF following treatment with IFN-γ, while B7-H3 was expressed on SF regardless of the presence of IFN-γ. Anti-cVIM positive RA patients’ sera recognized 54 kDa protein in SF. By co-immunoprecipitation using anti-vimentin and -citrulline antibodies, the 54 kDa protein recognized by RA sera was revealed to be citrullinated vimentin. Following induction of autophagy by serum-free starvation or proteasome inhibition, intracellular cVIM was increased in SF but the effect was cancelled by the autophagy inhibitor 3-methyladenin. The interaction between MHC class II and cVIM was demonstrated by co-immunoprecipitation. Furthermore, proximity ligation assay revealed that the MHC class II-cVIM interaction significantly increased following induction of autophagy.

Conclusion: Our current data indicate that SF contribute to the autoimmunity in RA through citrullination of vimentin and its interaction with MHC class II promoted by autophagy.


Disclosure: E. Sugawara, None; M. Kato, None; Y. Kudo, None; W. Lee, None; Y. Fujieda, None; T. Bohgaki, None; O. Amengual, None; K. Oku, None; S. Yasuda, None; T. Atsumi, None.

To cite this abstract in AMA style:

Sugawara E, Kato M, Kudo Y, Lee W, Fujieda Y, Bohgaki T, Amengual O, Oku K, Yasuda S, Atsumi T. Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/autophagy-promotes-citrullination-of-vimentin-and-its-interaction-with-major-histocompatibility-complex-class-ii-in-synovial-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autophagy-promotes-citrullination-of-vimentin-and-its-interaction-with-major-histocompatibility-complex-class-ii-in-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology